X-COR Therapeutics
X-COR Therapeutics provides a less invasive way to remove excess CO2 from patients with acute respiratory failure, enabling safer and more accessible respiratory support. The company offers a patent-pending medical device that uses a hybrid consumable cartridge and ultra-low blood flows (<300 ml/min) to extract CO2 through small catheters, together with a control algorithm that leverages machine-learning techniques. The system is designed to work with existing hospital device infrastructure and to be placed and managed with fewer specialized staff than high-flow extracorporeal alternatives. X-COR is a medical device company focused on hospital and critical-care settings where extracorporeal CO2 removal can reduce reliance on high-flow therapies. The technology targets clinicians treating symptomatic lung failure and aims to broaden access to extracorporeal CO2 removal.
X-COR Therapeutics
X-COR Therapeutics provides a less invasive way to remove excess CO2 from patients with acute respiratory failure, enabling safer and more accessible respiratory support. The company offers a patent-pending medical device that uses a hybrid consumable cartridge and ultra-low blood flows (<300 ml/min) to extract CO2 through small catheters, together with a control algorithm that leverages machine-learning techniques. The system is designed to work with existing hospital device infrastructure and to be placed and managed with fewer specialized staff than high-flow extracorporeal alternatives. X-COR is a medical device company focused on hospital and critical-care settings where extracorporeal CO2 removal can reduce reliance on high-flow therapies. The technology targets clinicians treating symptomatic lung failure and aims to broaden access to extracorporeal CO2 removal.